A Phase 2 interventional study of Ebselen and Placebo in Covid19, Coronavirus and Coronavirus Infection, sponsored by Sound Pharmaceuticals, Incorporated. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Sound Pharmaceuticals, Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 988th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 349 in phase 2, and was the 517th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Sound Pharmaceuticals, Incorporated is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Sound Pharmaceuticals, Incorporated has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19 disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral administration of matching placebo BID for 14 days, with 30-day follow-up
Drug: Placebo
Oral administration of SPI-1005 400 mg BID for 14 days, with 30-day follow-up
Drug: Ebselen
Glutathione peroxidase mimetic
Also known as: SPI-1005
Matching placebo containing excipients
Number of Participants With Treatment-related Adverse Events
Number of participants with adverse events, categorized by Common Terminology Criteria for Adverse Events (CTCAE) grading for severity.
Time frame: 30 days
WHO Ordinal Scale
Clinical outcome assessed by WHO Ordinal Scale for Clinical Improvement. Scale is 0-8 where higher score is worse outcome.
Time frame: 30 days
| Milestone | Placebo | SPI-1005 400 mg BID |
|---|---|---|
| Started | 9 | 16 |
| Completed | 6 | 10 |
| Not completed | 3 | 6 |
| Withdrew: Death | 1 | 4 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Subject non-compliant with study drug dosing | 0 | 1 |
Number of participants with adverse events, categorized by Common Terminology Criteria for Adverse Events (CTCAE) grading for severity.
| participants | Placebo | SPI-1005 400 mg BID |
|---|---|---|
| Grade 1 (Mild) | 2 | 6 |
| Grade 2 (Moderate) | 4 | 10 |
| Grade 3 (Severe) | 1 | 2 |
| Grade 4 (Life-Threatening) | 2 | 4 |
| Grade 5 (Death) | 1 | 2 |
Clinical outcome assessed by WHO Ordinal Scale for Clinical Improvement. Scale is 0-8 where higher score is worse outcome.
| units on a scale | Placebo | SPI-1005 400 mg BID |
|---|---|---|
| WHO Ordinal Scale | 2.33 ± 2.42 | 2.64 ± 2.01 |
Collected over 30 days, and up to 60 days for subjects who do not show resolution of clinical status and/or laboratory results on Day 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/9 (11.1%) | 3/9 (33.3%) | 1/9 (11.1%) |
| SPI-1005 400 mg BID | 4/16 (25%) | 5/16 (31.3%) | 8/16 (50%) |
| Event | Placebo | SPI-1005 400 mg BID |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/9 | 3/16 |
| SepsisInfections and infestations | 0/9 | 2/16 |
| Acute myocardial infarctionCardiac disorders | 1/9 | 0/16 |
| Alanine aminotransferase increasedInvestigations | 1/9 | 0/16 |
| Aspartate aminotransferase increasedInvestigations | 1/9 | 0/16 |
| PneumoniaInfections and infestations | 1/9 | 1/16 |
| HaematomaVascular disorders | 1/9 | 0/16 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/9 | 1/16 |
| ColitisGastrointestinal disorders | 0/9 | 1/16 |
| Small intestinal haemorrhageGastrointestinal disorders | 0/9 | 1/16 |
| Event | Placebo | SPI-1005 400 mg BID |
|---|---|---|
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/9 | 2/16 |
| Acute kidney injuryRenal and urinary disorders | 1/9 | 2/16 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/9 | 2/16 |
| TracheostomySurgical and medical procedures | 0/9 | 2/16 |
| Deep vein thrombosisVascular disorders | 0/9 | 2/16 |
| Age, Continuous(years) | Placebo | SPI-1005 400 mg BID | Total |
|---|---|---|---|
| Mean | 57.7 ± 16.7 | 54.8 ± 12.5 | 55.8 ± 13.9 |
| Sex: Female, Male(Participants) | Placebo | SPI-1005 400 mg BID | Total |
|---|---|---|---|
| Female | 4 | 8 | 12 |
| Male | 5 | 8 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | SPI-1005 400 mg BID | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 9 | 14 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | SPI-1005 400 mg BID | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 8 | 13 | 21 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | SPI-1005 400 mg BID | Total |
|---|---|---|---|
| United States | 9 | 16 | 25 |
| COVID-19 Vaccination(Participants) | Placebo | SPI-1005 400 mg BID | Total |
|---|---|---|---|
| Yes | 4 | 4 | 8 |
| No | 5 | 12 | 17 |
| WHO Ordinal Scale(units on a scale) | Placebo | SPI-1005 400 mg BID | Total |
|---|---|---|---|
| Mean | 5.44 ± 0.73 | 5.44 ± 0.63 | 5.44 ± 0.65 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in May 2023, 20 months.
Results were first posted in Jun 2026, 3 years 1 month after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 20 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ebselen
Sound Pharmaceuticals, Incorporated